JNJ-49095397

JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].

Product Specifications

CAS Number

[1220626-82-3]

Product Name Alternative

RV568

UNSPSC

12352005

Target

P38 MAPK; Src

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jnj-49095397.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=NC=CC(COC2=C3C=CC=CC3=C(NC(NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5)=O)C=C2)=C1)COC

Molecular Formula

C34H36N6O4

Molecular Weight

592.69

References & Citations

[1]Charron CE, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017 Oct 26;50 (4) :1700188.